The rebalancing agent concizumab has the potential to fulfil a need for new treatment options across all haemophilia subtypes but importantly for patients with haemophilia B and inhibitors. Speaking at the ISTH Congress, Associate Professor Jan Astermark said that the US FDA had recently designated the high-affinity humanised monoclonal antibody as a breakthrough therapy for ...
Breakthrough therapy for haemophilia B
By Mardi Chapman
24 Jul 2019